Synthesis and biological evaluation of novel heterocyclic quinones as inhibitors of the dual specificity protein phosphatase CDC25C.

Olivier Lavergne (1) , Anne-Cécile Fernandes (1) , Laetitia Bréhu (1) , Alban Sidhu (1) , Marie-Christine Brézak (1) , Grégoire Prévost (1) , Bernard Ducommun (2) , Marie-Odile Contour-Galcera (1)

1 IPSEN - Institut Henri Beaufour
2 LBCMCP - Laboratoire de Biologie Cellulaire et Moléculaire du Contrôle de la Prolifération

A focused set of heterocyclic quinones based on the benzothiazole, benzoxazole, benzimidazole, indazole and isoindole was prepared and screened with respect to the inhibition of the phosphatase activity of CDC25C. Benzoxazole- and benzothiazole-diones were at least 50 times more potent in inhibiting CDC25C than their benzimidazole-indazole- or isoindole-dione counterparts. These in vitro activities were in good correlation with the anti-proliferative effects observed with Mia PaCa-2 and DU-145 human tumor cell cultures. The IC(50) values obtained by WST-1 colorimetric assay ranged from 0.10 to 0.50 microM for the benzoxazole- or benzothiazole-diones and were above 10 microM for the other heterocyclic diones. This study further illustrates how the activity of the quinone pharmacophore can be selectively modulated by changing the type of five-membered heterocycle fused to the quinone ring.

Domaines: Biologie cellulaire

Olivier Lavergne, Anne-Cécile Fernandes, Laetitia Bréhu, Alban Sidhu, Marie-Christine Brézak, et al.. Synthesis and biological evaluation of novel heterocyclic quinones as inhibitors of the dual specificity protein phosphatase CDC25C.. Bioorganic and Medicinal Chemistry Letters, 2006, 16 (1), pp.171-175. ⟨10.1016/j.bmcl.2005.09.030⟩. ⟨hal-00317401⟩